

News Release

Lonza Announces Results of the 2018 Annual General Meeting – All Motions Proposed by Board of Directors Accepted

- 308 shareholders attended, representing 49.96% of the share capital
- Shareholders re-elected all existing members of the Board of Directors except for Rolf Soiron and Jean-Daniel Gerber, who did not stand for re-election, and approved the new elections of Angelica Kohlmann and Olivier Verscheure
- Albert M. Baehny was elected as Board Chairperson
- A dividend of CHF 2.75 per share will be paid out as from 11 May 2018

Basel, Switzerland, 4 May 2018 – Today's Annual General Meeting of Lonza Group Ltd, led by the Chairperson of the Board of Directors, Rolf Soiron, was attended by 308 shareholders. They represented 49.96% of the share capital.

The Board members standing for re-election (Patrick Aebischer, Werner Bauer, Albert M. Baehny, Christoph Mäder, Barbara Richmond, Margot Scheltema, Jürgen Steinemann and Antonio Trius) were all elected for a further term in office of one year. Rolf Soiron and Jean-Daniel Gerber did not stand for re-election.

The Annual General Meeting elected Albert M. Baehny as Chairperson of the Board of Directors for a term in office of one year. The shareholders also elected Angelica Kohlmann and Olivier Verscheure as new members of the Board; and Angelica Kohlmann, Christoph Mäder and Jürgen Steinemann as the three acting members of the Nomination and Compensation Committee.

The shareholders supported all other motions proposed by the Board of Directors, including among others the remuneration report and the binding votes on the compensation for the Board of Directors and the Executive Committee.

A dividend of CHF 2.75 per share, as proposed by the Board of Directors and accepted by the shareholders, will be paid out from 11 May 2018.

For further information, please see the short-form minutes of the Lonza Annual General Meeting 2018 under the following [link](#).

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

Lonza Contact Details

Dirk Oehlers, Head Investor Relations

Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dr Kristin Köhler, Senior Manager

Investor Relations
Lonza Group Ltd
Tel +41 61 316 8782
kristin.koehler@lonza.com

Dominik Werner, Head Corporate Communications

Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com

Constance Ward, Head External Communications

Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.